Age and Multimorbidity Predict Death Among COVID-19 Patients Results of the SARS-RAS Study of the Italian Society of Hypertension

Age and Multimorbidity Predict Death Among COVID-19 Patients Results of the SARS-RAS Study of the Italian Society of Hypertension
复制标题

DOI:
10.1161/hypertensionaha.120.15324
复制
发表时间:
2020-08-01
期刊:
影响因子:
8.3
通讯作者:
Volpe, Massimo
Volpe, Massimo
中科院分区:
医学1区
文献类型:
--
作者:
Iaccarino, Guido;Grassi, Guido;Volpe, Massimo

文献摘要

被引文献

相似文献

已经提出了几个因素来解释冠状病毒病2019年(新冠肺炎)爆发的高死亡率,包括高血压和高血压相关的肾素血管紧张素系统抑制剂治疗。此外,年龄和多发病可能是混杂因素。没有足够的数据可以证明它们的独立作用。我们在意大利设计了一项横断面、观察性、多中心、全国性的调查,以验证肾素-血管紧张素系统抑制剂是否与新冠肺炎的严重预后有关。我们分析了26家医院收治的被诊断为新冠肺炎的意大利患者的信息。共记录图表1,591张(男性64.1%,年龄66+/-0.4岁)。73.4%的患者有至少1种既往症状,以高血压最多见(54.9%)。有记录的死亡188人(11.8%;平均年龄79.6+/-0.9岁)。在死亡患者中,老年、高血压、糖尿病、慢性阻塞性肺疾病、慢性肾脏疾病、冠状动脉疾病和心力衰竭的发生率高于存活患者。死亡组Charlson共病指数显著高于存活组(4.3+/-0.15比2.6+/-0.05;P
Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66 +/- 0.4 years) were recorded. At least 1 preexisting condition was observed in 73.4% of patients, with hypertension being the most represented (54.9%). One hundred eighty-eight deaths were recorded (11.8%; mean age, 79.6 +/- 0.9 years). In nonsurvivors, older age, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery diseases, and heart failure were more represented than in survivors. The Charlson Comorbidity Index was significantly higher in nonsurvivors compared with survivors (4.3 +/- 0.15 versus 2.6 +/- 0.05;P